Dr. Peter Høngaard Andersen holds a B.Sc. in Chemistry, an M.Sc. in Biochemistry and a dr. medicine degree and has many years of experience and a broad network from his previous positions within the Life Science and biotech industries. Dr. Høngaard Andersen also has many years of experience in pharmaceutical research and development from the pharmaceutical industry working 30 years at Novo Nordisk in CNS, neuroendocrinology, women’s health and type-2 diabetes and at Lundbeck in CNS pharmaceutical research and early development. Dr. Høngaard Andersen has been involved in the research and development of several pharmaceuticals currently on the market (e.g., Norditropine Simplex, Victoza, Trintellix / Brintellix, Cipralex).
Dr. Høngaard Andersen has been a founder or co-founder of several biotech companies, including Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics and Prexton Pharmaceuticals. Dr. Høngaard Andersen was involved in the Innovative Medicines Initiative (IMI) from its inception in 2003 and served as Chairman of the industry side of IMI from 2009–2014.
Current assignments: Operating partner at Forbion, Chairperson of the Board of Directors in Kynexis BV.
Previous assignments (last five years): Founder and Managing Director of Innovation Fund Denmark, member of the Executive Committee of IC Permed (the International Consortium of Personalized Medicine), Chairperson of Prexton Therapeutics, the Board of Directors of Scandion Oncology A/S, the Innovation Board of the Danish Regional Council, Edvince AB and Venture Partner in Ysios Capital and a member of the Advisory Board in Eir Ventures.
Amount of shares in Immunovia: 11 730